Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
| Autor: | Sara Gianella, Bernard Hirschel, Andri Rauch, Matthias Cavassini, Enos Bernasconi, Manuel Battegay, Barbara Niederoest, Viktor von Wyl, Beda Joos, Huldrych F. Günthard, Herbert Kuster, Swiss Hiv Cohort Study-SHCS, Marek Fischer, Pietro Vernazza, Rainer Weber |
|---|---|
| Přispěvatelé: | Swiss HIV Cohort Study-SHCS, Weaver, Eric A, University of Zurich, von Wyl, V |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
Cross-sectional study Adult *Antiretroviral Therapy lcsh:Medicine HIV Infections 030312 virology Global Health 10234 Clinic for Infectious Diseases Cohort Studies 0302 clinical medicine immune system diseases Antiretroviral Therapy Highly Active HIV Seropositivity 030212 general & internal medicine Viral Longitudinal Studies lcsh:Science 0303 health sciences Multidisciplinary virus diseases HIV diagnosis and management Viral Load Antivirals 3. Good health Infectious Diseases HIV epidemiology 6.1 Pharmaceuticals Medicine Infectious diseases HIV/AIDS RNA Viral HIV clinical manifestations Biological Markers Female Infection Viral load Cohort study Research Article Cart Viral/blood Female Follow-Up Studies HIV Infections/*drug therapy/*virology HIV Seropositivity HIV-1/*genetics Humans Longitudinal Studies Male RNA Adult medicine.medical_specialty Drugs and Devices Infectious Disease Control Clinical Research Design General Science & Technology Antiretroviral Therapy Viral/blood *Viral Load 610 Medicine & health 1100 General Agricultural and Biological Sciences Viral diseases Microbiology Adult *Antiretroviral Therapy Highly Active Biomarkers/*blood CD4 Lymphocyte Count Case-Control Studies Cohort Studies Cross-Sectional Studies DNA Viral/blood Female Follow-Up Studies HIV Infections/*drug therapy/*virology HIV Seropositivity HIV-1/*genetics Humans Longitudinal Studies Male RNA Viral/blood *Viral Load 03 medical and health sciences 1300 General Biochemistry Genetics and Molecular Biology Clinical Research Internal medicine Virology mental disorders MD Multidisciplinary medicine Highly Active Biomarkers/*blood CD4 Lymphocyte Count Case-Control Studies Cohort Studies Cross-Sectional Studies DNA Humans Highly Active Seroconversion Biology 1000 Multidisciplinary business.industry lcsh:R Case-control study HIV Evaluation of treatments and therapeutic interventions DNA Antiretroviral therapy Confidence interval Swiss HIV Cohort Study-SHCS CD4 Lymphocyte Count Cross-Sectional Studies nervous system Case-Control Studies Immunology DNA Viral HIV-1 RNA lcsh:Q business Biomarkers Follow-Up Studies |
| Zdroj: | PLoS ONE, Vol 6, Iss 11, p e27463 (2011) Wyl, Viktor von; Gianella, Sara; Fischer, Marek; Niederoest, Barbara; Kuster, Herbert; Battegay, Manuel; et al.(2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.. PloS one, 6(11), e27463. doi: 10.1371/journal.pone.0027463. UC Office of the President: Research Grants Program Office (RGPO). Retrieved from: http://www.escholarship.org/uc/item/6c70z38x Plos One, vol. 6, no. 11, pp. e27463 PloS one, vol 6, iss 11 Wyl, Viktor von; Gianella, Sara; Fischer, Marek; Niederoest, Barbara; Kuster, Herbert; Battegay, Manuel; Bernasconi, Enos; Cavassini, Matthias; Rauch, Andri; Hirschel, Bernard; Vernazza, Pietro; Weber, Rainer; Joos, Beda; Günthard, Huldrych F; Swiss HIV Cohort Study-SHCS, (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11), e27463. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0027463 PLoS ONE PloS one |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0027463. |
| Popis: | Background: Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated. Methods: The evolution of plasma HIV-RNA (432 measurements) and cell-associated HIV-DNA (325 measurements) after cessation of cART (median exposure 18 months) was described for 33 participants from the Zurich Primary HIV Infection Study using linear regression and compared with 545 measurements from 79 untreated controls with clinically diagnosed primary HIV infection, respectively a known date for seroconversion. Results: On average, early treated individuals were followed for 37 months (median) after cART cessation; controls had 34 months of pre-cART follow-up. HIV-RNA levels one year after cART interruption were 20.8 log10 copies/mL [95% confidence interval 21.2;20.4] lower in early treated patients compared with controls, but this difference was no longer statistically significant by year three of follow-up (20.3 [20.9; 0.3]). Mean HIV-DNA levels rebounded from 2 log10 copies [1.8; 2.3] on cART to a stable plateau of 2.7 log10 copies [2.5; 3.0] attained 1 year after therapy stop, which was not significantly different from cross-sectional measurements of 9 untreated members of the control group (2.8 log10 copies [2.5; 3.1]). Conclusions: The rebound dynamics of viral markers after therapy cessation suggest that early cART may indeed limit reservoir size of latently infected cells, but that much of the initial benefits are only transient. Owing to the non-randomized study design the observed treatment effects must be interpreted with caution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|